The Rise, Fall and Future of Novavax 3/21/2023

University of Wyoming researchers' study of how microscopic creatures called tardigrades survive extreme conditions has led to a major breakthrough that could eventually make life-saving treatments available to people where refrigeration isn’t possible.

Thomas Boothby, an assistant professor of molecular biology, and colleagues have shown that natural and engineered versions of tardigrade proteins can be used to

FDA Releases Briefing Docs for Upcoming Biogen/Ionis Tofersen Adcomm 3/20/2023

Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo 3/20/2023

Karuna’s KarXT Aces Third Registrational Study in Schizophrenia 3/20/2023

Takeda Oncology Invests in Talent, Pipeline Growth Despite Turbulent Market 3/20/2023

Takeda’s $4B Plaque Psoriasis Candidate Clears Mid-Stage Study 3/20/2023

Raises for Moderna, Pfizer CEOs Highlight Continuing Trend 3/20/2023

FDA Action Alert: Biogen/Ionis, Cidara and Incyte 3/20/2023

Show Me the Money: US Life Sciences Salaries, By Region 3/20/2023

Novartis today announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.

Pfizer and Astellas Seek Expanded Label for Expensive Prostate Cancer Drug 3/17/2023

FDA Reverses Course; Will Hold Adcomm for Sarepta’s DMD Gene Therapy 3/17/2023

Amgen Cuts 450 Jobs in Second Round of Layoffs This Year 3/17/2023

Esperion-Daiichi Sankyo Partnership Saga Continues with Payment Spat 3/17/2023

In virtually all persons with amyotrophic lateral sclerosis (ALS) and in up to half of all cases of Alzheimer's disease (AD) and frontotemporal dementia, a protein called TDP-43 is lost from its normal location in the nucleus of the cell. In turn, this triggers the loss of stathmin-2, a protein crucial to regeneration of neurons and the maintenance of their connections to muscle fibers, essential to contraction and movement.

Seamless Launches with $12.5M for Programmable Recombinases Platform 3/16/2023

Aldena Raises $30M to Advance Skin-Deep siRNA Therapies 3/16/2023

Immuno-Oncology Pipeline Cuts Explained 3/16/2023

Is Job Hopping an Effective Career Advancement Strategy? 3/16/2023